These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

653 related articles for article (PubMed ID: 11079169)

  • 1. p53 mutations in epithelial ovarian cancers: possible role in predicting chemoresistance.
    Laframboise S; Chapman W; McLaughlin J; Andrulis IL
    Cancer J; 2000; 6(5):302-8. PubMed ID: 11079169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study.
    Havrilesky L; Darcy kM; Hamdan H; Priore RL; Leon J; Bell J; Berchuck A;
    J Clin Oncol; 2003 Oct; 21(20):3814-25. PubMed ID: 14551300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. P53 gene status in patients with advanced serous epithelial ovarian cancer in relation to response to paclitaxel- plus platinum-based chemotherapy and long-term clinical outcome.
    Gadducci A; Di Cristofano C; Zavaglia M; Giusti L; Menicagli M; Cosio S; Naccarato AG; Genazzani AR; Bevilacqua G; Cavazzana AO
    Anticancer Res; 2006; 26(1B):687-93. PubMed ID: 16739339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer.
    Reles A; Wen WH; Schmider A; Gee C; Runnebaum IB; Kilian U; Jones LA; El-Naggar A; Minguillon C; Schönborn I; Reich O; Kreienberg R; Lichtenegger W; Press MF
    Clin Cancer Res; 2001 Oct; 7(10):2984-97. PubMed ID: 11595686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p53 status is neither a predictive nor a prognostic variable in patients with advanced ovarian cancer treated with a paclitaxel-based regimen.
    Gadducci A; Cianci C; Cosio S; Carnino F; Fanucchi A; Buttitta F; Conte PF; Genazzani AR
    Anticancer Res; 2000; 20(6C):4793-9. PubMed ID: 11205220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantification of p53 in epithelial ovarian cancer.
    Geisler JP; Geisler HE; Wiemann MC; Givens SS; Zhou Z; Miller GA
    Gynecol Oncol; 1997 Sep; 66(3):435-8. PubMed ID: 9299258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma.
    Righetti SC; Della Torre G; Pilotti S; Ménard S; Ottone F; Colnaghi MI; Pierotti MA; Lavarino C; Cornarotti M; Oriana S; Böhm S; Bresciani GL; Spatti G; Zunino F
    Cancer Res; 1996 Feb; 56(4):689-93. PubMed ID: 8630996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy.
    Levesque MA; Katsaros D; Massobrio M; Genta F; Yu H; Richiardi G; Fracchioli S; Durando A; Arisio R; Diamandis EP
    Clin Cancer Res; 2000 Aug; 6(8):3260-70. PubMed ID: 10955812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombospondin-1 expression in epithelial ovarian carcinoma: association with p53 status, tumor angiogenesis, and survival in platinum-treated patients.
    Alvarez AA; Axelrod JR; Whitaker RS; Isner PD; Bentley RC; Dodge RK; Rodriguez GC
    Gynecol Oncol; 2001 Aug; 82(2):273-8. PubMed ID: 11531279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p53 mutation is infrequent in clear cell carcinoma of the ovary.
    Ho ES; Lai CR; Hsieh YT; Chen JT; Lin AJ; Hung MH; Liu FS
    Gynecol Oncol; 2001 Feb; 80(2):189-93. PubMed ID: 11161858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients.
    Kandioler-Eckersberger D; Ludwig C; Rudas M; Kappel S; Janschek E; Wenzel C; Schlagbauer-Wadl H; Mittlböck M; Gnant M; Steger G; Jakesz R
    Clin Cancer Res; 2000 Jan; 6(1):50-6. PubMed ID: 10656431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relationship of molecular markers of p53 function and angiogenesis to prognosis of stage I epithelial ovarian cancer.
    Goodheart MJ; Ritchie JM; Rose SL; Fruehauf JP; De Young BR; Buller RE
    Clin Cancer Res; 2005 May; 11(10):3733-42. PubMed ID: 15897570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
    Berns EM; Foekens JA; Vossen R; Look MP; Devilee P; Henzen-Logmans SC; van Staveren IL; van Putten WL; Inganäs M; Meijer-van Gelder ME; Cornelisse C; Claassen CJ; Portengen H; Bakker B; Klijn JG
    Cancer Res; 2000 Apr; 60(8):2155-62. PubMed ID: 10786679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutation and expression of the TP53 gene in early stage epithelial ovarian carcinoma.
    Leitao MM; Soslow RA; Baergen RN; Olvera N; Arroyo C; Boyd J
    Gynecol Oncol; 2004 May; 93(2):301-6. PubMed ID: 15099937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
    Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
    Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human papilloma virus (HPV) status, p16INK4a, and p53 overexpression in epithelial malignant and borderline ovarian neoplasms.
    Giordano G; Azzoni C; D'Adda T; Rocco A; Gnetti L; Froio E; Merisio C; Melpignano M
    Pathol Res Pract; 2008; 204(3):163-74. PubMed ID: 18180113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. P53 mutation does not affect prognosis in ovarian epithelial malignancies.
    Fallows S; Price J; Atkinson RJ; Johnston PG; Hickey I; Russell SE
    J Pathol; 2001 May; 194(1):68-75. PubMed ID: 11329143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53 mutations do not predict response to paclitaxel/radiation for nonsmall cell lung carcinoma.
    Safran H; King T; Choy H; Gollerkeri A; Kwakwa H; Lopez F; Cole B; Myers J; Tarpey J; Rosmarin A
    Cancer; 1996 Sep; 78(6):1203-10. PubMed ID: 8826941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of the tumor suppressor gene ARHI in epithelial ovarian cancer is associated with increased expression of p21WAF1/CIP1 and prolonged progression-free survival.
    Rosen DG; Wang L; Jain AN; Lu KH; Luo RZ; Yu Y; Liu J; Bast RC
    Clin Cancer Res; 2004 Oct; 10(19):6559-66. PubMed ID: 15475444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p53 alteration is not an independent prognostic indicator, but affects the efficacy of adjuvant chemotherapy in human pancreatic cancer.
    Dong M; Nio Y; Yamasawa K; Toga T; Yue L; Harada T
    J Surg Oncol; 2003 Feb; 82(2):111-20. PubMed ID: 12561067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.